Docosapentaenoic Acid (n-3)

lipid · cardiovascular · Oral

Docosapentaenoic Acid (n-3), a lipid. 22:5 ω-3 PUFA positioned between EPA (20:5) and DHA (22:6) in the ω-3 elongation/desaturation pathway.… Oral half-life 6.4 d.

22:5 ω-3 PUFA positioned between EPA (20:5) and DHA (22:6) in the ω-3 elongation/desaturation pathway. Retroconverts to EPA in humans and is a direct substrate for resolvin and protectin biosynthesis; preferentially incorporated into platelets and vascular endothelium. Typically a minor component of fish oil (~1–5% of EPA+DHA) but enriched in seal oil and in some green-lipped-mussel preparations. Primary human data are epidemiologic (plasma n-3 DPA inversely associated with CV events) rather than pharmacokinetic.

Pharmacokinetics

• Oral — t½ 6.4 d

Related compounds

• EPA/DHA — synergistic

Sources: PMID:27151222